Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.

Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.

Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”

PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.

Key features of the facility include:

The site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence.